¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 26ÀÏ (1ÀÏÂ÷) : 2021-08-26

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 26ÀÏ (1ÀÏÂ÷) : 2021-08-26
±³À°ÀÏÀÚ : 2021-08-26
±³À°Àå¼Ò : ¿Â¶óÀΠ 
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 26ÀÏ (1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ
´ã´çÀÚ : À±ÁöÇö
¿¬¶ôó : 070-4895-6129  
À̸ÞÀÏ : bmt@kams.or.kr      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú      
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 20,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-26 CH A 09:30~10:00 NGS-based MRD Monitoring Pre- and Post-Allogeneic HSCT for AML  Michael Heuser(MHH Hospital) 
±³À°½Ã°£ 08-26 CH A 10:00~10:30 Conditioning Intensity of Allogeneic Transplantation for AML with MRD  Christopher S. Hourigan(NIH) 
±³À°½Ã°£ 08-26 CH A 10:40~11:10 Engineering and Design for Next Generation CAR-T Cells  Sham Mailankody(MSKCC) 
±³À°½Ã°£ 08-26 CH A 11:20~11:50 Machine Learning Research for Hematopoietic Stem Cell Transplantation  Yasuyuki Arai(Kyoto University) 
±³À°½Ã°£ 08-26 CH A 11:50~12:20 Current Statistical Issues in Hematopoietic Cell Transplantation  Haesook T. Kim(Dana-Farber Cancer Institute) 
±³À°½Ã°£ 08-26 CH B 12:40~13:20 Optimizing Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation  Thomas Martin(University of California San Francisco) 
±³À°½Ã°£ 08-26 CH A 13:30~14:30 Risk factors and outcomes of cytomegalovirus infection in children post cord blood transplantation with focus on impact of graft-versus-host disease and immunosuppressants  Eun Sang Yi(Korea University Guro Hospital) 
±³À°½Ã°£ 08-26 CH A 14:40~15:10 High Throughput Single Cell Analysis in AML  Koichi Takahashi(MDACC) 
±³À°½Ã°£ 08-26 CH A 15:10~15:40 Therapeutic Implications in AML using Prospective Genomic Profiling  Omar Abdel-Wahab(MSKCC) 
±³À°½Ã°£ 08-26 CH A 15:40~16:10 Clonal Hematopiesis of Indeterminate Potential in Transplantation  Kyoung Ha Kim(Soonchunhyang University Hospital) 
±³À°½Ã°£ 08-26 CH A 16:30~17:00 FLT3 Inhibitor Maintenance Therapy after Allogeneic HSCT in FLT3 Mutated AML  Richard T. Maziarz(Oregon Health and Science University) 
±³À°½Ã°£ 08-26 CH A 17:00~17:30 Maintenance Therapy (Hypomethylating Agents, Bcl2-Inhibitor, Check Point Inhibitors, and Other Novel Drugs) after Allogeneic HSCT in AML and MDS  Tapan Kadia(MDACC) 
±³À°½Ã°£ 08-26 CH A 17:30~18:00 Treatment Strategies after Allogeneic HSCT in Relapsed ALL  Ik-Chan Song(Chungnam National University College of Medicine) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 26ÀÏ (1ÀÏÂ÷) : 2021-08-26""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 27ÀÏ (2ÀÏÂ÷) : 2021-08-27
´ÙÀ½±Û (¿Â¶óÀÎ) Á¦19ȸ ±è¾È°úº´¿ø ½ÉÆ÷Áö¾ö : 2021-08-22
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20574 °­¿ø ´ëÇÑÁ¤Çü¿Ü°ú¿¬±¸ÇÐȸ - 2024³â Ãá°è½ÉÆ÷Áö¾ö (2ÀÏÂ÷) : 2024-06-08 0 33 2024-04-29
20573 ¼­¿ï °æÈñ´ëÇб³º´¿ø 2024 Kyung Hee Knee Symposium : 2024-06-08 0 44 2024-04-29
20572 ¼­¿ï 2024³â ´ëÇѽÉÇ÷°ü¾à¹°Ä¡·áÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-08 0 43 2024-04-29
20571 ¼­¿ï (¿Â¶óÀÎ) 2024³â ´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ °¨¿°°ü¸®ÀÇ»ç ¿¬¼ö±³À° : 2024-06-08 0 46 2024-04-29
20570 Á¦ÁÖ 2024³â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ Á¦ÁÖÁöȸ ¿¬¼ö°­Á : 2024-06-08 0 45 2024-04-29
20569 ¼­¿ï 2024 ´ëÇÑÇ÷¾×ÇÐȸ ¼Ò¾Æû¼Ò³â ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ 1Â÷ ½ÉÆ÷Áö¾ö : 2024-06-08 0 38 2024-04-29
20568 °­¿ø ´ëÇÑÁ¤Çü¿Ü°ú¿¬±¸ÇÐȸ - 2024³â Ãá°è½ÉÆ÷Áö¾ö (1ÀÏÂ÷) : 2024-06-07 0 44 2024-04-29
20567 ´ëÀü Á¦114Â÷ ´ëÇѽŰæ¿Ü°úÇÐȸ ´ëÀüÃæûÁöȸ Á¤±âÇмú´ëȸ : 2024-06-07 0 38 2024-04-29
20566 ´ë±¸ ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ ´ë±¸°æºÏÁöȸ Áý´ãȸ : 2024-06-04 0 39 2024-04-29
20565 ¼­¿ï Á¦24ȸ ´ëÇÑ°»³â±âÇÐȸ 2024 Ãá°èÇмú´ëȸ : 2024-06-02 0 27 2024-04-29
20564 ¼­¿ï 2024 ´ëÇÑÄ¡¸ÅÇÐȸ Ä¡¸ÅƯº°µî±Þ ÀÇ»ç¼Ò°ß¼­ ÀÛ¼º ±³À° : 2024-06-02 0 43 2024-04-29
20563 ¼­¿ï ÀÌ´ë¼­¿ïº´¿ø °³¿ø 5Áֳ⠱â³ä ¿Ü°ú ½ÉÆ÷Áö¾ö ¹× °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-02 0 51 2024-04-29
20562 ¼­¿ï Á¦ 14Â÷ ´ëÇѸð¹ßÀ̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ(2ÀÏÂ÷) : 2024-06-02 0 37 2024-04-29
20561 ¼­¿ï ´ëÇÑÁ·ºÎÁ·°üÀýÇÐȸ IFFAS 2024 (3ÀÏÂ÷) : 2024-06-01 0 55 2024-04-29
20560 °æ±â 2024 ¼º³²½ÃÀÇ»çȸ »ó¹Ý±â Çмú´ëȸ : 2024-06-01 0 41 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷